secwatch / observer
8-K filed March 3, 2025, 6:59 PM ET ticker DAKT CIK 0000915779
other material confidence high sentiment positive materiality 0.75

Daktronics settles with Alta Fox, appoints Peter Feigin to board, ends poison pill

DAKTRONICS INC /SD/

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Peter Feigin

Director
DAKT · DAKTRONICS INC /SD/
Effective
2025-03-05
Filed
March 3, 2025, 6:59 PM ET
On March 3, 2025, the Board appointed Peter Feigin to serve as a member of the Board, effective March 5, 2025, with a term expiring at the 2027 Annual Meeting.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter Feigin was appointed as Director at DAKTRONICS INC /SD/.

Action
appointed
Role
Director
Exact text from the filing
On March 3, 2025, the Board appointed Peter Feigin to serve as a member of the Board, effective March 5, 2025, with a term expiring at the 2027 Annual Meeting.
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

DAKTRONICS INC /SD/: Amended bylaws to require a Lead Independent Director if the Board Chair is not an independent director (effective 2025-03-03).

Change
bylaw amendment
Effective
2025-03-03
Exact text from the filing
The Amended Bylaws codify the Company’s existing practice, as contemplated by the Company’s Board of Directors Corporate Governance Guidelines, by amending the Bylaws to require the directors to select a Lead Independent Director in the event that the Chairperson of the Board is not an Independent Director.
View on SEC.gov

190 governance changes filed in the last 30 days. Browse all governance changes →

DAKTRONICS INC /SD/ filing history →

Source: SEC EDGAR
accession 0001193125-25-044301
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.